Researchers from Philochem AG recently reported the discovered OncoFAP, a high-affinity small organic ligand of fibroblast activation protein (FAP) that has shown rapid accumulation in tumors and low uptake in healthy tissues in preclinical models.

Angiogenesis plays a crucial role in multiple myeloma and its prognosis, with the success of antiangiogenic therapies being limited. Exosomes mediate cell-to-cell cross talk during the progression of cancer by transporting their molecular cargo, which include long non-coding RNAs (lncRNAs); their role in multiple myeloma was investigated.

Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.

Systemic sclerosis is an autoimmune disorder characterized by inflammation, vasculopathy and fibrosis, mainly affecting internal organs and the skin. There is still a lack of therapies for SSc-induced skin fibrosis.

B-cell lymphoma 6 (BCL6) is up-regulated in several B-cell malignancies where it acts as a transcription factor activity mediator to induce and maintain lymphomagenesis.

Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas.

The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.